[Corrections] Correction to Lancet Oncol 2017; 18: 1061–75

Perl AE, Altman JK, Cortes J, et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study. Lancet Oncol 2017; 18: 1061–75—In table S9 in the supplementary appendix of this Article, the composite remission in patients with ITD and D835 mutations should have been 7 (54%). The appendix has been corrected as of Nov 29, 2017.

http://ift.tt/2kacAka